These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 20623701)

  • 21. Sphingosine-1-phosphate (S1P) displays sustained S1P1 receptor agonism and signaling through S1P lyase-dependent receptor recycling.
    Gatfield J; Monnier L; Studer R; Bolli MH; Steiner B; Nayler O
    Cell Signal; 2014 Jul; 26(7):1576-88. PubMed ID: 24704119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans.
    Biliouris K; Nestorov I; Naik H; Dai D; Xiao G; Wang Q; Pellerin A; Rabah D; Lesko LJ; Trame MN
    J Pharmacokinet Pharmacodyn; 2018 Dec; 45(6):817-827. PubMed ID: 30377889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic/pharmacodynamic modelling of 2-acetyl-4(5)-tetrahydroxybutyl imidazole-induced peripheral lymphocyte sequestration through increasing lymphoid sphingosine 1-phosphate.
    Yu XQ; Kramer J; Moran L; O'Neill E; Nouraldeen A; Oravecz T; Wilson AG
    Xenobiotica; 2010 May; 40(5):350-6. PubMed ID: 20175664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for erythropenia in rats.
    Kobuchi S; Ito Y; Hayakawa T; Nishimura A; Shibata N; Takada K; Sakaeda T
    J Pharmacol Toxicol Methods; 2014; 70(2):134-44. PubMed ID: 25072509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sphingosine-1-phosphate signalling-a key player in the pathogenesis of Angiotensin II-induced hypertension.
    Meissner A; Miro F; Jiménez-Altayó F; Jurado A; Vila E; Planas AM
    Cardiovasc Res; 2017 Feb; 113(2):123-133. PubMed ID: 28082452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.
    Schuck E; Bohnert T; Chakravarty A; Damian-Iordache V; Gibson C; Hsu CP; Heimbach T; Krishnatry AS; Liederer BM; Lin J; Maurer T; Mettetal JT; Mudra DR; Nijsen MJ; Raybon J; Schroeder P; Schuck V; Suryawanshi S; Su Y; Trapa P; Tsai A; Vakilynejad M; Wang S; Wong H
    AAPS J; 2015 Mar; 17(2):462-73. PubMed ID: 25630504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Semi-physiological pharmacokinetic-pharmacodynamic modeling and simulation of 5-fluorouracil for the whole time course of alterations in leukocyte, neutrophil and lymphocyte counts in rats.
    Kobuchi S; Ito Y; Hayakawa T; Kuwano S; Baba A; Shinohara K; Nishimura A; Shibata N; Takada K
    Xenobiotica; 2014 Sep; 44(9):804-18. PubMed ID: 24650147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach.
    Meno-Tetang GM; Lowe PJ
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):182-92. PubMed ID: 15733213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic and pharmacodynamic comparability study of moxetumomab pasudotox, an immunotoxin targeting CD22, in cynomolgus monkeys.
    Wang B; Liang M; Yao Z; Vainshtein I; Lee R; Schneider A; Zusmanovich M; Jin F; O'Connor K; Donato-Weinstein B; Iciek L; Lavallee T; Roskos L
    J Pharm Sci; 2013 Jan; 102(1):250-61. PubMed ID: 23090886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects.
    Kovarik JM; Schmouder R; Barilla D; Riviere GJ; Wang Y; Hunt T
    J Clin Pharmacol; 2004 May; 44(5):532-7. PubMed ID: 15102874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-Density Lipoprotein-Associated Apolipoprotein M Limits Endothelial Inflammation by Delivering Sphingosine-1-Phosphate to the Sphingosine-1-Phosphate Receptor 1.
    Ruiz M; Frej C; Holmér A; Guo LJ; Tran S; Dahlbäck B
    Arterioscler Thromb Vasc Biol; 2017 Jan; 37(1):118-129. PubMed ID: 27879252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody.
    Fu J; Wang F; Dong LH; Zhang J; Deng CL; Wang XL; Xie XY; Zhang J; Deng RX; Zhang LB; Wu H; Feng H; Chen B; Song HF
    Acta Pharmacol Sin; 2017 May; 38(5):710-718. PubMed ID: 28317872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human plasma concentrations of cytochrome P450 probes extrapolated from pharmacokinetics in cynomolgus monkeys using physiologically based pharmacokinetic modeling.
    Shida S; Utoh M; Murayama N; Shimizu M; Uno Y; Yamazaki H
    Xenobiotica; 2015; 45(10):881-6. PubMed ID: 26075833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism-based PK/PD model for the lymphocytopenia induced by endogenous and exogenous corticosteroids.
    Meibohm B; Derendorf H; Möllmann H; Fröhlich P; Tromm A; Wagner M; Homrighausen S; Krieg M; Hochhaus G
    Int J Clin Pharmacol Ther; 1999 Aug; 37(8):367-76. PubMed ID: 10475139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sphingosine-1-phosphate induced vasoconstriction is increased in the isolated perfused kidneys of diabetic rats.
    Bautista-Pérez R; Arellano A; Franco M; Osorio H; Coronel I
    Diabetes Res Clin Pract; 2011 Oct; 94(1):e8-11. PubMed ID: 21775010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sphingosine-1-Phosphate/Sphingosine-1-Phosphate Receptor 2 Axis Can Promote Mouse and Human Primary Mast Cell Angiogenic Potential through Upregulation of Vascular Endothelial Growth Factor-A and Matrix Metalloproteinase-2.
    Chumanevich A; Wedman P; Oskeritzian CA
    Mediators Inflamm; 2016; 2016():1503206. PubMed ID: 26884643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetic and pharmacodynamic modeling of different formulations of ONO-5334, cathepsin K inhibitor, in Caucasian and Japanese postmenopausal females.
    Hasegawa C; Ohno T; Umemura T; Honda N; Ohyama M; Nagase S; Small M; Deacon S; Ogawa M; Ieiri I
    J Clin Pharmacol; 2014 Jan; 54(1):23-34. PubMed ID: 24115072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Osteoblastic cells express phospholipid receptors and phosphatases and proliferate in response to sphingosine-1-phosphate.
    Grey A; Xu X; Hill B; Watson M; Callon K; Reid IR; Cornish J
    Calcif Tissue Int; 2004 Jun; 74(6):542-50. PubMed ID: 15354862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2-Aryl(pyrrolidin-4-yl)acetic acids are potent agonists of sphingosine-1-phosphate (S1P) receptors.
    Yan L; Budhu R; Huo P; Lynch CL; Hale JJ; Mills SG; Hajdu R; Keohane CA; Rosenbach MJ; Milligan JA; Shei GJ; Chrebet G; Bergstrom J; Card D; Mandala SM
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3564-8. PubMed ID: 16621543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways.
    Zollinger M; Gschwind HP; Jin Y; Sayer C; Zécri F; Hartmann S
    Drug Metab Dispos; 2011 Feb; 39(2):199-207. PubMed ID: 21045200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.